Literature DB >> 7967208

Clinical features of HTLV-I associated uveitis determined in multicenter collaborative study. Study Group for HTLV-I Associated Ocular Diseases.

N Ohba1, K Nakao, Y Isashiki, T Kaminagayoshi, S Sonoda, S Yashiki, M Osame.   

Abstract

The elucidation of the clinical features of human T-lymphotropic virus type I (HTLV-I) associated uveitis (HAU) was advanced by the results of a multicenter study performed by the collaboration of university hospitals throughout Kyushu and Okinawa and two institutions in the Tokyo-Yokohama metropolitan areas of Japan. A total of 426 cases of endogenous uveitis were registered during the five-month study period between September 1992 and January 1993. The etiology and clinical entity remained unknown for about half of these cases. A series of 50 cases of HTLV-I seropositive, entity-undefined uveitis were suspected to be HAU, and analyses of these cases provided the following clinical features of this recently defined uveitis entity. 1) middle-aged adult of either sex develops acute, inflammatory uveal disease and presents with visual haze or floaters, or both; 2) active disease consists of granulomatous or nongranulomatous reactions accompanied by vitreous opacities and retinal vasculitis with rare retinochoroidal exudative changes; 3) the disease resolves with response to corticosteroids, although leaving sequelae in occasional cases; 4) the disease affects one or both eyes, and up to half of cases show recurrent disease within years; 5) the visual outcome is usually favorable; 6) the disease occurs as an isolated disorder, but may sometimes be complicated by HTLV-I associated myelopathy. Hyperthyroidism is also associated in occasional cases; 7) the titer of serum HTLV-I antibodies is significantly high compared with that of HTLV-I carriers, suggesting an immune mechanism as the pathogenesis of HAU.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7967208

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  7 in total

1.  Retinal vascular inflammatory and occlusive changes in infectious and non-infectious uveitis.

Authors:  Toshikatsu Kaburaki; Hisako Fukunaga; Rie Tanaka; Hisae Nakahara; Hidetoshi Kawashima; Shintaro Shirahama; Hidetomo Izawa; Keiko Komae; Mitsuko Takamoto; Hirotsugu Soga; Makoto Aihara
Journal:  Jpn J Ophthalmol       Date:  2020-02-03       Impact factor: 2.447

2.  HTLV-I associated uveitis revisited: characteristic grey-white, granular deposits on retinal vessels.

Authors:  K Nakao; N Ohba
Journal:  Br J Ophthalmol       Date:  1996-08       Impact factor: 4.638

Review 3.  Clinical and Public Health Implications of Human T-Lymphotropic Virus Type 1 Infection.

Authors:  Nicolas Legrand; Skye McGregor; Rowena Bull; Sahar Bajis; Braulio Mark Valencia; Amrita Ronnachit; Lloyd Einsiedel; Antoine Gessain; John Kaldor; Marianne Martinello
Journal:  Clin Microbiol Rev       Date:  2022-02-23       Impact factor: 50.129

4.  HTLV-I associated uveitis in central Japan.

Authors:  K Goto; K Saeki; M Kurita; S Ohno
Journal:  Br J Ophthalmol       Date:  1995-11       Impact factor: 4.638

5.  Case Report: Orbital Tumor Revealing Adult T-Cell Leukemia/Lymphoma Associated with Human T-Cell Lymphotropic Virus Type-1.

Authors:  Selim Farès; Rabih Hage; Jean Pegliasco; Samy Chraibi; Harold Merle
Journal:  Am J Trop Med Hyg       Date:  2018-06-28       Impact factor: 2.345

Review 6.  Updates on HTLV-1 Uveitis.

Authors:  Koju Kamoi; Toshiki Watanabe; Kaoru Uchimaru; Akihiko Okayama; Seiko Kato; Toyotaka Kawamata; Hisako Kurozumi-Karube; Noe Horiguchi; Yuan Zong; Yoshihisa Yamano; Isao Hamaguchi; Yasuhito Nannya; Arinobu Tojo; Kyoko Ohno-Matsui
Journal:  Viruses       Date:  2022-04-12       Impact factor: 5.818

7.  Panuveitis induced by donor-derived CD8+ T cells after allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia.

Authors:  Atsunobu Takeda; Teppei Sakoda; Nobuyo Yawata; Koji Kato; Eiichi Hasegawa; Takahiro Shima; Shinichi Hikita; Keiko Yoshitomi; Katsuto Takenaka; Yoshinao Oda; Koichi Akashi; Koh-Hei Sonoda
Journal:  Am J Ophthalmol Case Rep       Date:  2022-08-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.